Could a shorter drug course work just as well for older AML patients?
NCT ID NCT07437950
First seen Feb 28, 2026 · Last updated Apr 28, 2026 · Updated 11 times
Summary
This study looks at whether giving the drug venetoclax for a shorter time, along with the combination drug ASTX727, is as effective as the usual longer course for adults aged 60 and older with newly diagnosed acute myeloid leukemia (AML) who cannot tolerate intensive chemotherapy. About 126 participants will be randomly assigned to one of two treatment schedules. The goal is to see if the shorter treatment can achieve similar rates of deep remission with fewer side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.